Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
75% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. VSTM: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VSTM' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Interest Coverage No Debt
VSTM's Interest Coverage is ranked lower than
53% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VSTM' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 13.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -53.56
VSTM's ROE (%) is ranked lower than
65% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. VSTM: -53.56 )
Ranked among companies with meaningful ROE (%) only.
VSTM' s 10-Year ROE (%) Range
Min: -82.34  Med: -51.76 Max: -39.63
Current: -53.56
-82.34
-39.63
ROA (%) -49.40
VSTM's ROA (%) is ranked lower than
68% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. VSTM: -49.40 )
Ranked among companies with meaningful ROA (%) only.
VSTM' s 10-Year ROA (%) Range
Min: -47.67  Med: -42.10 Max: -37.77
Current: -49.4
-47.67
-37.77
ROC (Joel Greenblatt) (%) -2673.21
VSTM's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. VSTM: -2673.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VSTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.21  Med: -5742.30 Max: -3102.26
Current: -2673.21
-7948.21
-3102.26
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VSTM Guru Trades in Q2 2014

First Eagle Investment 512,254 sh (+0.20%)
Paul Tudor Jones Sold Out
» More
Q3 2014

VSTM Guru Trades in Q3 2014

Jim Simons 66,300 sh (New)
First Eagle Investment 512,254 sh (unchged)
» More
Q4 2014

VSTM Guru Trades in Q4 2014

Jim Simons 204,787 sh (+208.88%)
First Eagle Investment 302,622 sh (-40.92%)
» More
Q1 2015

VSTM Guru Trades in Q1 2015

Paul Tudor Jones 10,666 sh (New)
First Eagle Investment 427,622 sh (+41.31%)
Jim Simons 107,100 sh (-47.70%)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.95
VSTM's P/B is ranked higher than
82% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. VSTM: 1.95 )
Ranked among companies with meaningful P/B only.
VSTM' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 4.9
Current: 1.95
0
4.9
EV-to-EBIT -2.26
VSTM's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. VSTM: -2.26 )
Ranked among companies with meaningful EV-to-EBIT only.
VSTM' s 10-Year EV-to-EBIT Range
Min: 0  Med: 0.00 Max: 0
Current: -2.26
Current Ratio 14.26
VSTM's Current Ratio is ranked higher than
84% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. VSTM: 14.26 )
Ranked among companies with meaningful Current Ratio only.
VSTM' s 10-Year Current Ratio Range
Min: 10.36  Med: 14.26 Max: 30.79
Current: 14.26
10.36
30.79
Quick Ratio 14.26
VSTM's Quick Ratio is ranked higher than
85% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. VSTM: 14.26 )
Ranked among companies with meaningful Quick Ratio only.
VSTM' s 10-Year Quick Ratio Range
Min: 10.36  Med: 14.26 Max: 30.79
Current: 14.26
10.36
30.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.15
VSTM's Price/Net Cash is ranked higher than
91% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. VSTM: 2.15 )
Ranked among companies with meaningful Price/Net Cash only.
VSTM' s 10-Year Price/Net Cash Range
Min: 2.57  Med: 3.13 Max: 6.04
Current: 2.15
2.57
6.04
Price/Net Current Asset Value 2.10
VSTM's Price/Net Current Asset Value is ranked higher than
91% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. VSTM: 2.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VSTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.55  Med: 3.08 Max: 5.97
Current: 2.1
2.55
5.97
Price/Tangible Book 1.98
VSTM's Price/Tangible Book is ranked higher than
85% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. VSTM: 1.98 )
Ranked among companies with meaningful Price/Tangible Book only.
VSTM' s 10-Year Price/Tangible Book Range
Min: 1.98  Med: 2.46 Max: 3.87
Current: 1.98
1.98
3.87
Earnings Yield (Greenblatt) (%) -44.20
VSTM's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. VSTM: -44.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VSTM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -60.4  Med: 0.00 Max: 0
Current: -44.2
-60.4
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 2 6
EPS($) -1.83 -2.12 -2.50
EPS without NRI($) -1.83 -2.12 -2.50

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany,
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including mesothelioma, ovarian and lung. The Company's solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company's competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Biotech Pharma with Approaching FDA Decision Catalyst Aug 04 2015
Verastem to Present at Cantor Fitzgerald’s Inaugural Health Care Conference Jul 02 2015
Verastem to Present at Cantor Fitzgerald’s Inaugural Health Care Conference Jul 02 2015
Verastem to Present at 2015 JMP Securities Life Sciences Conference Jun 17 2015
Verastem to Present at 2015 JMP Securities Life Sciences Conference Jun 17 2015
Verastem Announces Executive Management Changes Jun 10 2015
VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 10 2015
Verastem Announces Executive Management Changes Jun 10 2015
UPDATE 1-Large U.S. cancer trial to match genetic glitches to targeted drugs Jun 01 2015
Large U.S. cancer trial to match genetic glitches to targeted drugs Jun 01 2015
Verastem to Present at Jefferies 2015 Healthcare Conference May 27 2015
Verastem to Present at Jefferies 2015 Healthcare Conference May 27 2015
Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting May 19 2015
Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting May 19 2015
The Road To The Cure: 4 Biotech Stocks Advancing New Therapies In The Fight Against Cancer May 17 2015
VERASTEM, INC. Financials May 16 2015
Verastem to Present at 2015 UBS Global Health Care Conference May 12 2015
Verastem to Present at 2015 UBS Global Health Care Conference May 12 2015
Verastem reports 1Q loss May 11 2015
Verastem reports 1Q loss May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK